CDR132L

DRUG5 trials

Sponsors

Cardior Pharmaceuticals GmbH, Novo Nordisk A/S

Conditions

Heart FailureHeart Failure With Preserved Ejection FractionHeart Failure, Left SidedMyocardial Infarction, Acute

Phase 1

Clinical Study to Assess Safety, PK and PD Parameters of CDR132L

CompletedNCT04045405

Cardior Pharmaceuticals GmbHHeart Failure

Start: 2019-06-21End: 2020-06-26Updated: 2026-01-09

Phase 2

Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction

CompletedNCT05350969

Cardior Pharmaceuticals GmbHHeart Failure, Left Sided, Myocardial Infarction, Acute

Start: 2022-07-11End: 2025-03-17Updated: 2026-08-26

Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy

WithdrawnNCT05953831

Cardior Pharmaceuticals GmbHHeart Failure With Preserved Ejection Fraction

Start: 2024-04-30End: 2025-09-30Updated: 2026-07-07

A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

RecruitingNCT06979375

Novo Nordisk A/SHeart Failure

Start: 2025-06-30End: 2028-01-23Target: 200Updated: 2026-03-11

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

RecruitingNCT06979362

Novo Nordisk A/SHeart Failure

Start: 2025-06-27End: 2028-07-25Target: 200Updated: 2026-08-05

Related Papers

The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial

Nature Medicine2026-05-10

MiR-132 inhibition improves myocardial strain in a large animal model of chronic left ventricular adverse remodelling

European Heart Journal - Imaging Methods and Practice2025-07-01

Abstract 15115: Efficacy and Safety of miR-132 Inhibitor CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction: Rationale for and Design of the HF-REVERT Trial

Circulation2023-11-071 citations

Abstract 15057: miR-132 Inhibitor CDR 132L Attenuates Cardiac Remodeling by Exhibiting Anti-Fibrotic Effects

Circulation2023-11-071 citations

Abstract 15185: Plasma miR-132 Serves as a Blood Biomarker for Monitoring Treatment Efficacy of miR-132 Targeting Drugs Using a Novel CE-Marked Kit System

Circulation2023-11-07

Abstract 15096: miR-132 Inhibition Shows Anti-Hypertrophic Effects in Preclinical Heart Failure Models and in Exploratory Pharmacodynamic Parameters of a First-in-Human Phase 1b Clinical Trial

Circulation2023-11-07

Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study

European Heart Journal2020-10-16354 citations

CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure

European Heart Journal2020-09-10151 citations

Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease.

2020-02-27162 citations